research Multi-omics analysis unveils the role of cancer-associated fibroblasts in cutaneous squamous cell carcinoma
Cancer-associated fibroblasts promote tumor growth in skin cancer.
Search
for
Sort by
Research
960-990 / 1000+ resultsresearch Table S1. Disease-dependent differences between tape-strip and bulk biopsy ssGSEA scores across hair follicle compartments
research Table S1. Disease-dependent differences between tape-strip and bulk biopsy ssGSEA scores across hair follicle compartments
research 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.
research Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling
Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.
research 572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma
Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
research Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma
Lower SMAD2/3 activation predicts more severe skin cancer.
research 9. Immunology and Genetics
The document concludes that Borrelia afzelii causes a skin condition in France, a gene is linked to hair loss in Caucasian women, and various genetic mutations affect skin diseases.
research 342 COMPARISON OF THE INCIDENCE OF SECONDARY CANCERS AFTER IMRT, BRACHYTHERAPY AND SURGERY FOR THE TREATMENT OF PROSTATE CANCER
Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.
research Cytokeratins as Markers of Follicular Differentiation
TB and BCC tumors show similar follicular differentiation patterns.
research The importance of basonuclin 2 in adult mice and its relation to basonuclin 1
Basonuclin 2 is vital for the development of facial bones, hair follicles, and male germ cells in adult mice, and its absence can lead to dwarfism and abnormal follicles.
research Scalp Involvement in Primary Cutaneous Lymphomas—An Update on Clinical Presentation, Diagnostics, and Management
Scalp involvement in primary cutaneous lymphomas is common and can be aggressive, requiring careful attention.
research Linear Basal Cell Carcinomas
Dr. Connelly agrees that linear basal cell carcinomas might be more aggressive but highlights the study's lack of clear criteria to identify them.
research UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
research Skin Deep and Deeper: Multiple Pathways in Basal Cell Carcinogenesis
The research suggests new treatments for skin cancer could target specific cell growth pathways.
research The extracellular matrix dictates regional competence for tumour initiation
The extracellular matrix affects where tumors can start in the body.
research Coexistence of bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata: a case report of multifactorial autoimmunity in a surgical context
Bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata may share immune-related causes.
research Bicalutamide 25 mg associated with minoxidil 1 mg versus minoxidil 1 mg for female-pattern hair loss: A randomized double-blind clinical trial
Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
research Egr-1 is main key regulator in IL-17F-induced psoriasin expression in human keratinocytes
Psoriasis is linked to a higher risk of autoimmune diseases and other health conditions.
research Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
Baricitinib effectively treats severe alopecia for up to 104 weeks.
research Decision letter: Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes
Moles may stop growing due to cell cooperation, not just because of individual cell aging.
research Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
research Abstract P5-11-11: A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
research The Role of Ischemia-modified Albumin and Ischemia-modified Albumin to Albumin Ratios in Patients with Alopecia Areata
IMA and IMA/albumin levels don't predict alopecia areata severity.
research Skin stem cells and tumor growth : functions of collagen XVIII in hair follicle cycling and skin cancer, and Bmx tyrosine kinase in tumor angiogenesis
Collagen XVIII and Bmx tyrosine kinase are important for hair growth and skin cancer development.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research What’s new in Birt–Hogg–Dubé syndrome?
New findings suggest the protein linked to Birt–Hogg–Dubé syndrome is important in cell signaling and could affect treatment understanding.
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
research Assessment of monocyte to high density lipoprotein ratio and ischemia-modified albumin in acne vulgaris patients
Higher ischemia-modified albumin levels are linked to acne severity.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.